Millennium Management
SGMT icon

Millennium Management’s Sagimet Biosciences SGMT Stock Holding History

Millennium Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.24M Buy
937,025
+74,722
+9% +$508K ﹤0.01% 2645
2026
Q1 		$4.51M Buy
862,303
+275,356
+47% +$1.53M ﹤0.01% 3071
2025
Q4 		$3.47M Sell
586,947
-189,430
-24% -$1.36M ﹤0.01% 3409
2025
Q3 		$5.33M Buy
776,377
+700,737
+926% +$5.68M ﹤0.01% 3085
2025
Q2 		$576K Sell
75,640
-85,272
-53% -$360K ﹤0.01% 4810
2025
Q1 		$525K Sell
160,912
-532,335
-77% -$2.23M ﹤0.01% 4784
2024
Q4 		$3.12M Buy
693,247
+499,094
+257% +$2.53M ﹤0.01% 3267
2024
Q3 		$538K Sell
194,153
-382,596
-66% -$1.18M ﹤0.01% 4769
2024
Q2 		$1.97M Sell
576,749
-43,678
-7% -$200K ﹤0.01% 3546
2024
Q1 		$3.36M Buy
620,427
+572,376
+1,191% +$4.11M ﹤0.01% 3270
2023
Q4 		$260K Buy
48,051
+35,820
+293% +$169K ﹤0.01% 5035
2023
Q3 		$108K Buy
+12,231
New +$163K ﹤0.01% 5317

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Millennium Management's SGMT Position: Q2 2026 in Review

Millennium Management increased its Sagimet Biosciences (SGMT) stake by 8.7% in Q2 2026, buying an estimated $508K and bringing the position to 937,025 shares worth $7.24M. The position accounts for ﹤0.01% of the portfolio, ranked #2645.

Millennium Management first reported a position in SGMT in Q3 2023 and has held it in 12 quarters since. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Millennium Management held 937,025 shares of Sagimet Biosciences worth $7.24M as of Q2 2026.
  • Millennium Management bought 74,722 Sagimet Biosciences shares in Q2 2026, an estimated $508K.
  • Sagimet Biosciences made up ﹤0.01% of Millennium Management's portfolio in Q2 2026, its #2645 holding.
  • Millennium Management first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 12 quarters since.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.